Events
Dr. Bejar will be in attendance and will present on the 'Clinical Impact of Somatic Mutations in MDS’ on September, 20th at 10:45 AM.
Dr. Bejar and Dr. Park will be in attendance at the American Society of Clinical Oncology Annual Meeting in Chicago.
Bejar Lab was ‘Green Labs Certified’ on April 30th 2019. Tim Luger will be present at the sustainability awards ceremony on Thursday, May 9th at 3:00 PM to accept the award on behalf of the lab.
Dr. Bejar, Dr. Park and Brian Reilly will be attending the 15th International Symposium on MDS in Copenhagen. Brian Reilly’s abstract on the ‘Role of TET2 in DNA Methylation and Gene Expression Dynamics Following 5-Azacytidine’ was accepted for the event and he will be present to discuss his findings. Additionally, Brian will have a poster available for viewing during the poster sessions and breaks. Dr. Bejar will present on Friday May 10th from 12:10 PM - 12:30 PM on the ‘Genetic Changes Underlying Ineffective Erythropoiesis.’ Dr. Park is receiving the MDS Young Investigator Award and will be giving a brief presentation on May 11th from 11:09 AM -11:21 AM on the ‘Use of Metformin for Prevention of Clonal Progression to Therapy-Related MDS/AML.’
Dr. Bejar, Dr. Tanaka and Dr. Park will be in attendance at the Acute Leukemia Forum. Dr. Bejar will be present as a moderator for the Session 2 discussions on the Advances in Myelodysplasia on Thursday, April 11th starting at 3:00 PM.
Dr. Bejar will be in attendance at the meeting in Albuquerque on Saturday March 30th. At 9:00 AM he will will present on the state of Myelodysplastic Syndromes: Diagnosis, Treatment and Research.
https://aamdsif.salsalabs.org/2019PFCAlbuquerqueNewMexico/index.html
Dr. Bejar will be attending the Great Debates and Updates in Hematologic Malignancies meeting in Los Angeles.
Dr. Bejar will be attending the MDS + AML Matter Summit in San Francisco California.
The entire lab will be in attendance for ASH 2018 in San Diego California. Brian Reilly will present ‘DNA Methylation Identifies Genetically and Prognostically Distinct Subtypes of MDS’ on Saturday, December 1st at 9:30 AM in Seaport Ballroom A at the Grand Hyatt.
Dr. Bejar will present ‘Genetic and Epigenetic Features of MDS and Their Clinical Significance’ at MD Anderson’s Grand Rounds on November 7th at 8 AM.
Dr. Bejar has been invited to present at the 15th annual Uruguay Congress of Hematology. He will present ‘Biologia molecular en Sindromes Mielodisplasicos’ at 4:35 PM on Thursday, October 18th. Additionally, he will present ‘Estudio Molecular’ at 2:30 PM on Friday, October 19th.
Dr. Bejar will present at the 37th Annual World Congress for the International Society of Hematology. In his session on Saturday, September 15th at 3:30 PM, he will discuss the role of next generation sequencing on MDS prognosis.
Dr. Bejar will discuss how he incorporates myeloid mutation testing to treat MDS on Friday, September 7th at 10:30 AM at the Meeting on Hematologic Malignancies.
Dr. Bejar will be presenting at the MDS Symposia in several cities: Shanghai, Suzhou, Tianjin and Beijing China from June 18 through the 21st.
Dr. Bejar will be attending the hematology seminar at Brigham and Women’s Hospital.
Dr. Bejar has been invited to speak at the Carolinas Healthcare System Grand Rounds.
Dr. Bejar was invited to speak at Grand Rounds for the Josep Carreras Leukaemia Research Institute.
Dr. Bejar will be presenting at the MFAR Next-Generation Sequencing Course in Valencia, Spain.
Dr. Bejar will be speaking at the Celgene Myeloid Expert Workshop in Seoul, Korea on 4/26/2018
Dr. Bejar will be presenting his talk, What biologic factors predict for transformation to AML?, at the forum.
Dr. Bejar will be presenting at the MDS Foundation Patient and Family Forum on Saturday, February 3rd, 2018.
https://www.mds-foundation.org/event/mds-foundation-patient-and-family-forum-san-diego-ca/
Dr. Bejar will be presenting on Anemia Aplásica. Criterios diagnósticos y su Tratamiento at the AMEH Hematology Review.
Dr. Rafael Bejar, Dr. Tiffany Tanaka and Dr. Soo Park will be attending the 59th ASH Annual Meeting and Exposition in Atlanta Georgia.
In Malaga, Spain Dr. Bejar will present 'SÍNDROMES MIELODISPLÁSICOS EN LA ERA MOLECULAR – MDS in the molecular Era'
At the 79th Annual Meeting of the JSH Dr. Bejar will present the 'Clinical Implications of Clonal Hematopoiesis'
Additionally, Dr. will attend the Nippon Shinyaku Seminar and present 'The Impact of Somatic and Germline Mutations in Myelodysplastic Syndromes'
Dr. Bejar will present and discuss 'Clonal Hematopoiesis in Relation to MDS/AML' at the 4th International Conference on AML.
Dr. Bejar will address the question: 'Are We Gaining Any Ground in Myelodysplastic Syndromes?' Additionally, Dr. Bejar will present 'What We Need to Know about Risk Stratification in Myelodysplastic Syndromes' at the 2017 symposium.
On Thursday, May 4th as part of the 'Promises and Pitfalls of Next Gen Sequencing for Diagnosis,' plenary session Dr. Bejar will present 'MDS Somatic Mutations: a Role for Improving Diagnosis and Risk Assessment?' to symposium attendees.
Additionally, Dr. Bejar will participate in the Celgene Symposium by presenting the 'Importance of molecular screening: how can mutational data inform treatment for MDS patients?'
For the MPN and MDS session, Dr. Bejar will debate the topic of whether molecular genetic testing should be routinely performed in cases of older persons with cytopenias/possible MDS, for the affirmative position.
http://imedex.com/hematologic-malignancies-debate-conference/archive/2017/agenda.asp
Dr. Bejar will present 'Clonal Hematopoiesis as a Precancerous State' as part of the 'Precancer Genome Atlas Seminar' at the 2017 Annual AACR meeting in Washing D.C.
